Hangzhou AGS Medtech CoSHSE:688581 -0.89%87 ROA % is 8.45% as of Mar. 2026, which is 55% below its 10-year median of 18.89. GuruFocus rates SHSE:688581 with a GF Score™ of 87/100 and a GF Value™ of ¥74.30 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 856 Medical Devices & Instruments companies, Hangzhou AGS Medtech Co ranks better than 83.29% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Hangzhou AGS Medtech Co's annualizedNet Income for the quarter that ended in Mar. 2026 was ¥227.2 Mil.
Hangzhou AGS Medtech Co's average Total Assets over the quarter that ended in Mar. 2026 was ¥2,687.4 Mil. Therefore, Hangzhou AGS Medtech Co's annualized ROA % for the quarter that ended in Mar. 2026 was 8.45%.
The historical rank and industry rank for Hangzhou AGS Medtech Co's ROA % or its related term are showing as below:
SHSE:688581'
s ROA % Range Over the Past 10 Years
Min: -22.99 Med: 18.89 Max: 35.57
Current: 8.44
During the past 9 years, Hangzhou AGS Medtech Co's highest ROA % was 35.57%. The lowest was -22.99%. And the median was 18.89%.
SHSE:688581's ROA % is ranked better than 83.29% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.545
vs SHSE:688581: 8.44
Hangzhou AGS Medtech Co (SHSE:688581) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Hangzhou AGS Medtech Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou AGS Medtech Co ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hangzhou AGS Medtech Co's ROA % distribution charts can be found below:
* The bar in red indicates where Hangzhou AGS Medtech Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Hangzhou AGS Medtech Co (SHSE:688581) has a ROA % of 8.45% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Hangzhou AGS Medtech Co and its competitors. This is 55% below median its historical median of 18.89. According to the industry distribution chart, Hangzhou AGS Medtech Co ranks #143 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 16.7%.
Is Hangzhou AGS Medtech Co's ROA % too high?
Hangzhou AGS Medtech Co's current ROA % of 8.45% is 55% below median its 10-year median of 18.89. The Medical Devices & Instruments industry median ROA % is 0.55. Hangzhou AGS Medtech Co's value of 8.45% is 1450.5% above this industry median. Based on the distribution chart, Hangzhou AGS Medtech Co ranks #143 out of 856 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Hangzhou AGS Medtech Co has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou AGS Medtech Co's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Hangzhou AGS Medtech Co ranks #143 out of 856 companies for ROA %. This places Hangzhou AGS Medtech Co in the top 17% of its industry — outperforming the majority of peers. The industry median ROA % is 0.55. Hangzhou AGS Medtech Co's value of 8.45% is 1450.5% above this benchmark. While the company's 10-year median is 18.89 vs. the industry median of 0.55, Hangzhou AGS Medtech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.55, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou AGS Medtech Co's current ROA % of 8.45% is 1450.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Hangzhou AGS Medtech Co and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou AGS Medtech Co's current ROA % is 8.45%, which is 55% below median its own 10-year median of 18.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou AGS Medtech Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou AGS Medtech Co (SHSE:688581) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥74.30, compared to a current price of ¥55.70 — trading 25% below its estimated fair value. The current ROA % is 8.45%, which is 55% below median its 10-year median of 18.89 and 1450.5% above the Medical Devices & Instruments industry median of 0.55. Hangzhou AGS Medtech Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Hangzhou AGS Medtech Co (SHSE:688581), the current ROA % is 8.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou AGS Medtech Co (SHSE:688581) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou AGS Medtech Co stock appears to be undervalued.
The current stock price of ¥55.70 is trading 25% below its estimated GF Value™ of ¥74.30.
GuruFocus considers Hangzhou AGS Medtech Co to be Modestly Undervalued.
Key valuation signals for SHSE:688581:
ROA %: 8.45% (55% below median its 10-year median of 18.89)
GF Value™: ¥74.30 vs. price of ¥55.70 (25% below fair value)
Industry Position: 1450.5% above the Medical Devices & Instruments median (#143 of 856)
No single metric tells the full story. See the SHSE:688581 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou AGS Medtech Co Ltd is engaged in Research & Development, production, and sales of endoscopic minimally invasive diagnosis and treatment devices. The company upholds the core values of create, insist, share, and provide patients and clinicians with safer and more efficient minimally invasive endoscopic devices, helping patients reduce pain and medical costs.
87GF Score
Get the complete analysis for SHSE:688581
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688581 has been successfully added to your 
